Summary
The precondition for the antineoplastic effect of ifosfamide (ifo) is the oxidation of the oxazaphosphorine ring system, which contains a chiral centre at the phosphorous atom. This “ring oxidation” leads to the formation of alkylating mustard via several steps. A second metabolic pathway produces the cytostatically inactive metabolites 2- and 3-dechloroethyl-ifosfamide (2-d- and 3-d-ifo). The urinary excretion of the optical isomers of unmetabolised ifo and of 2- and 3-d-ifo, which represents the amount of ifo that has not been activated, was investigated by capillary gas chromatography for 18 treatment cycles in 14 children on various therapeutic schedules. The total cumulative excretion in 12 completely sampled cycles ranged from 27% to 50% of the ifo dose. Between 14% and 34% of the dose could be detected as ifo; 9% to 29%, as 3-d-ifo; and 2% to 8%, as 2-d-ifo. At 24 h after the end of therapy, excretion was nearly complete. Without exception, slightly more R-ifo (53%–61%) than S-ifo was excreted. S-2-d-ifo (50%–73%) was the main 2-d-metabolite. S-3-d-ifo (deriving from R-ifo) predominated in 6 of 14 children and R-3-d-ifo, in 8. Enantiomer-specific excretion increased after the end of infusion (up to 73% for R-ifo and 27% for S-ifo). We demonstrated stereospecific metabolism of ifo in children, with two different patterns of side-chain oxidation being observed. There was no evidence of important stereospecific ring oxidation in most children. A benefit should not be expected from the therapeutic application of pure enantiomers.
Similar content being viewed by others
References
Allen LM, Creaven PJ (1972) In vitro activation of isophosphamide (NSC-109 724), a new oxazaphosphorine, by rat liver microsomes. Cancer Chemother Rep 56: 603–610
Allen LM, Creaven PJ, Nelson RL (1976) Studies on the human pharmacokinetics of ifosfamide (NCI-109 724). Cancer Treat Rep 60: 451–458
Blaschke G, Koch U (1986) Untersuchungen zum stereoselektiven Metabolismus von Ifosfamid. Arch Pharmacol 319: 1052
Blaschke G, Widey W (1989) Metabolismus der Enantiomere des Zytostatikums Ifosfamid. Arzneimittelforschung 39(1): 223–226
Blaschke G, Hilgard P, Maibaum J, Niemeyer U, Pohl J (1986) Präparative Trennung der Ifosfamid-Enantiomere und ihre pharmakologisch-toxikologische Untersuchung. Arzneimittelforschung 36 (II): 1493–1495
Cerny T, Castiglione M, Brunner K, Küpfer A, Martinelli G, Lind M (1990) Ifostamide by continuous infusion to prevent encephalopathy. Lancet I: 175
Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M (1973) Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 23: 115–129
Cox PJ, Farmer PB, Jarman M, Jones M, Stec WJ, Kinas R (1976) Observations on the differential metabolism and biological activity of the optical isomers of cyclophosphamide. Biochem Pharmacol 25: 993–996
Cox PJ, Farmer PB, Jarman M, Kinas RW, Stec WJ (1978) Stereoselectivity in the metabolism of the enantiomers of cyclophosphamide in mice, rats and rabbits. Drug Metab Dispos 6: 617–622
Delepine N, Taillard F, Desbois JG, Cornille H, Delepine G, Jasmin C (1986) CNS-side effects induced by ifosfamide-mesna in children with osteosarcomas. Biomed Pharmacother 40: 173–175
Farmer PB (1988) Enantiomers of cyclophosphamide and iphosphamide. Biochem Pharmacol 37: 145–148
Goren MP, Wright RK, Pratt CB, Pell FE (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet II: 1219–1220
Goren MP, Wright RK, Horowitz ME, Pratt CB (1987) Ifosfamide induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 71: 127–130
Goren MP, Pratt CB, Viar MJ (1989) Tubular nephrotoxicity during long-term ifosfamide and mesna therapy. Cancer Chemother Pharmacol 25: 70–72
Heim ME, Fiene R, Schick E, Wolpert E, Queißer W (1981) Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol 100: 113–116
Hill DL, Russel Laster W, Kirk MC, El Dareer S, Struck RF (1973) Metabolism of iphosphamide [2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3-2-oxazaphosphorine-2-oxide] and production of a toxic iphosphamide metabolite. Cancer Res 33: 1016–1022
Jürgens H, Treuner J, Winkler K, Göbel U (1989) Ifosfamide in pediatric malignancies. Semin Oncol 16 [Suppl 3]: 46–50
Kellie SJ, Pritchard J, Bowman A, Kraker J de, Lilleyman JS (1987) Ifosfamide neurotoxicity in children. J Clin Oncol 5: 512–514
Kusnierczyk H, Radzikowski C, Paprocka M, Budzynski W, Rak J, Kinas R, Misiura K, Stec W (1986) Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates. J Immunopharmacol 8: 455–480
Lewis LD, Meanwell CA (1990) Ifosfamide pharmacokinetics and neurotoxicity. Lancet I: 175–196
Lind J, Roberts HL, Thatcher N, Idle JR (1990) The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 26: 105–111
Masurel D, Houghton PJ, Young CL, Wainer I (1990) Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice. Cancer Res 50: 252–255
Misiura K, Okruszek A, Pankiewicz K, Stec WJ, Czownicki Z, Utracka B (1983) Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine. J Med Chem 26: 674–679
Moncrieff M, Foot A (1989) Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 23: 121–122
Newbury-Ecob rA, Noble VW, Barbor PRH (1989) Ifosfamide-induced Fanconi syndrome. Lancet I: 1328
Ninane J, Baurain R, Kraker J de, Ferster A, Trouet A, Cornu G (1989) Alkylating activity in serum, urine and CSF following high-dose ifosfamide in children. Cancer Chemother Pharmacol 24 [Suppl]: 82–86
Norpoth K, Addicks HW, Witting U, Müller G, Raidt H (1975) Quantitative Bestimmung von Cyclophosphamid, Ifosfamid und Trofosfamid sowie ihrer stabilen Metabolite auf der DC-Platte mit 4-Pyridinaldehyd-2-benzothiazolylhydrazon (PHB). Arzneimittelforschung 25: 1331–1336
Patterson WP, Khojaseh A (1989) Ifosfamide-induced renal tubular defects. Cancer 63: 649–651
Pearcey R, Calvert R, Mehta A (1988) Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma. Cancer Chemother Pharmacol 22: 353–355
Pinkerton CA, Philip T, Brunat Mentigney M (1985) Ifosfamide, mesna, and encephalopathy. Lancet I: 1399
Pratt CB, Green AA, Horowitz ME, Meyer WH, Etcubanas E, Douglass E, Hayes FA, Thompson E, Wilimas J, Igarashi M, Kovnar E (1986) Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 4: 1253–1261
Salloum E, Flamant F, Goshn M, Taleb N, Akatchereian C (1987) Irreversible encephalopathy with ifosfamide/mesna. J Clin Oncol 5: 1303–1304
Skinner R, Pearson ADJ, Price L, Coulthard MG, Craft AW (1989) Nephrotoxicity of ifosfamide in children. Lancet II: 159
Skinner R, Pearson ADJ, Price L, Cunningham K, Craft AW (1989) Hypophosphataemic rickets after ifosfamide treatment in children. BMJ 298: 1560–1561
Smeitink J, Verreussel M, Schröder C, Lippens R (1988) Nephrotoxicity associated with ifosfamide. Eur J Pediatr 148: 164–166
Watkin SW, Husband DJ, Green JA, Warenius HM (1989) Ifosfamide encephalopathy: a reappraisal. Eur J Cancer Clin Oncol 1303–1310
Author information
Authors and Affiliations
Additional information
This research was financially supported by the Deutsche Forschungsgemeinschaft
Rights and permissions
About this article
Cite this article
Boos, J., Welslau, U., Ritter, J. et al. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother. Pharmacol. 28, 455–460 (1991). https://doi.org/10.1007/BF00685822
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685822